Related Experiment Video
Updated: Jun 1, 2026
11:25
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Summary
Patients with Philadelphia chromosome-positive chronic myeloid leukemia treated with busulfan may have a better prognosis if they require less of the drug during their first year of therapy. This finding suggests a link between busulfan dosage and disease progression.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Interferon alpha is a primary treatment for chronic myeloid leukemia (CML).
- Conventional chemotherapy agents like hydroxyurea and busulfan are used for patients ineligible for interferon alpha therapy.
- Philadelphia chromosome-positive CML requires specific treatment considerations.
Purpose of the Study:
- To investigate the relationship between busulfan dosage and disease progression in CML patients.
- To determine if the total amount of busulfan required in the first year predicts the duration of the chronic phase.
- To identify potential prognostic indicators for busulfan-treated CML.
Main Methods:
- Retrospective analysis of 23 patients with Philadelphia chromosome-positive CML.
- Patients were treated exclusively with busulfan.
- Evaluation of the correlation between total busulfan dosage in the first 12 months and the length of the chronic phase.
Main Results:
- A statistically significant inverse relationship was observed (p<0.005).
- Patients requiring lower total busulfan amounts in the first year showed a longer chronic phase duration.
- This suggests a correlation between initial drug requirement and patient prognosis.
Conclusions:
- Lower busulfan requirement in the initial treatment year is associated with a better prognosis in Philadelphia chromosome-positive CML.
- Busulfan dosage may serve as a predictive marker for disease course.
- Further research into busulfan's role in CML management is warranted.
